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Abstract
Background:  Cisplatin mediates its antineoplastic activity by formation of distinct DNA
intrastrand cross links. The clinical efficacy and desirable dose escalations of cisplatin are restricted
by the accumulation of DNA lesions in dorsal root ganglion (DRG) cells leading to sensory
polyneuropathy (PNP). We investigated in a mouse model by which mechanism recombinant
erythropoietin (rhEPO) protects the peripheral nervous system from structural and functional
damage caused by cisplatin treatment with special emphasis on DNA damage burden.
Results: A cumulative dose of 16 mg cisplatin/kg resulted in clear electrophysiological signs of
neuropathy, which were significantly attenuated by concomitant erythropoietin (cisplatin 32,48 m/
s ± 1,68 m/s; cisplatin + rhEPO 49,66 m/s ± 1,26 m/s; control 55,01 m/s ± 1,88 m/s; p < 0,001). The
co-application of rhEPO, however, did not alter the level of unrepaired cisplatin-DNA lesions
accumulating in DRG target cells. Micro-morphological analyses of the sciatic nerve from cisplatin-
exposed mice showed damaged myelin sheaths and mitochondria. Co-administered rhEPO
inhibited myelin sheaths from structural injuries and resulted in an increased number of intact
mitochondria.
Conclusion: The protective effect of recombinant erythropoietin is not mediated by reducing the
burden of DNA platination in the target cells, but it is likely to be due to a higher resistance of the
target cells to the adverse effect of DNA damage. The increased frequency of intact mitochondria
might also contribute to this protective role.
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Background
The antineoplastic efficacy of treatment regimens with cis-
platin (cis-diaminodichloro-platinum [II]) is hampered
by its severe neurotoxic side-effects [1], which frequently
limit the continuation of treatment cycles. Patients com-
plain of distal paresthesis, loss of joint position resulting
in sensory ataxia [2,3]. Sural nerve biopsies showed
degeneration of large myelinated axons with signs of seg-
mental demyelinization and remyelinization [3,4]. Elec-
trophysiological findings revealed decreased sensory
nerve conduction velocity and SAP-amplitudes [5,6].
The anti-tumor activity as well as the toxicity in physiolog-
ical cells are mediated by the formation of specific cispla-
tin-DNA adducts with guanine-guanine intrastrand cross-
links (cisPt(NH3)2d(pGpG; Pt-GG), representing the
majority (~70%) of the DNA platination products. Accu-
mulation and persistence of these DNA lesions can inter-
fere with replication or transcription and trigger apoptotic
processes [7,8]. To counteract the deleterious effects of
DNA damage, mammalian cells are equipped with vari-
ous DNA repair mechanisms. The most efficient pathway
to remove Pt-GG adducts is nucleotide excision repair
(NER) [9,10].
In a mouse model of cisplatin-induced neurotoxicity we
have recently shown that Pt-GG adducts are not com-
pletely eliminated from the nuclear DNA of distinct neu-
ronal cell types [11]. Repeated application of cisplatin
resulted in an accumulation of persisting DNA cross-links
in DRG neurons in parallel to decreased sensory nerve
conduction velocities and their corresponding ampli-
tudes. These effects were significantly accelerated in mice
with a functional defect in NER [11].
Neuroprotective strategies might aim either at a reduced
accumulation of drug-induced DNA adducts or at
improved survival or function of critical cells despite of
their actual damage burden. There is increasing evidence
for the protective properties of erythropoietin (EPO) in
neuronal tissues [12-16]. Such effects have been demon-
strated both for intrinsic EPO as well as for pharmacolog-
ical application of rhEPO [17,18]. Erythropoietin is a
pleiotropic cytokine mediating its hematopoietic effects
via homodimeric erythropoietin receptors (EpoR), which
are expressed also in various neuronal tissues [13,19-21].
In the peripheral nervous system EPO and EpoR were
proven to be present in DRG neurons, axons and
Schwann cells [13]. Peripheral nerve injury led to aug-
mented levels of both molecules [13,21] and to the activa-
tion of an "axono-protective" pathway via EpoR ligation
in neurons [21].
By employing behavioral, electrophysiological and micro
morphological techniques, we have investigated in our
mouse model the potency of rhEPO to inhibit the periph-
eral neuropathy during exposure to cisplatin. To further
elucidate the underlying mechanism, we have analyzed,
in particular, whether co-application of this cytokine
interfered with the accumulation of Cisplatin-DNA
adducts in DRG neurons.
Results
Recombinant human erythropoietin extenuates cisplatin-
induced neuropathy
Repetitive applications of cisplatin (2 mg/kg/week) for 8
weeks resulted in a highly significant decrease of sensory
nerve conduction velocity (SNCV) by ~40% compared to
control (Figure 1). In our experiment rhEPO had a partial
but highly significant protective effect despite values
being different from controls (cisplatin 32,48 m/s ± 1,68
m/s; cisplatin + rhEPO 49,66 m/s ± 1,26 m/s; rhEPO 51,6
m/s ± 2,81 m/s; control 55,01 m/s ± 1,88 m/s; ANOVA df
= 3, F = 25; p < 0,001). The corresponding H-amplitude
was decelerated by ~60% compared to controls (cisplatin
0,21 μV ± 0,02 μV; cisplatin + rhEPO 0,46 μV ± 0,1 μV;
rhEPO 0,53 μV ± 0,07 μV; control 0,57 μV ± 0,1 μV;
ANOVA df = 3; F = 4,4; p < 0,05). In accordance with ear-
lier findings [11] the nerve conduction velocities for the
motor function (MNCV) were only slightly decelerated
after a cumulated dose of 16 mg cisplatin/kg, however the
corresponding M-amplitude was again significantly
reduced compared to controls (cisplatin 1,55 μV ± 0,2 μV;
cisplatin + rhEPO 2,82 μV ± 0,39 μV; rhEPO 2,81 μV ±
0,27 μV; control 3,14 μV ± 0,29 μV; ANOVA do = 3; F =
6,3; p < 0,05).
No renal damage following cisplatin treatment
As nephrotoxicity is a common side effect of cisplatin
chemotherapy all mice were given i.p. injections of 0.5 ml
saline after each single dose of cisplatin. To further
exclude that renal failure might modulate the nerve con-
ductivity we determined parameters for kidney function
in animals from all groups. Significant differences were
observed neither for the serum creatinine status nor for
the creatinine clearance (data not shown). This finding
was confirmed by histopathological examinations of the
kidneys showing no signs of renal damage and a normal
morphology of glomerulae, microvillus and tubulus epi-
thelium cells in all tissue samples examined.
Mechanical sensitivity is improved by rhEPO
In addition to decreased nerve conduction velocity and
sensory loss, the peripheral neuropathy can paradoxically
also be associated with allodynia as observed in patients
and in animal systems [22]. To analyze whether the co-
application of rhEPO also modulates the somatic hyper-
sensitivity we measured the withdrawal threshold after
mechanical stimulation of the hind paw.BMC Neuroscience 2009, 10:77 http://www.biomedcentral.com/1471-2202/10/77
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Mice treated with a cumulative dose of 16 mg/kg cisplatin
showed clear signs of somatic hypersensitivity, resulting
in a significant reduction in withdrawal threshold as com-
pared to controls (Figure 2). Concomitant treatment with
rhEPO lacked statistical significance (p = 0.313). Mice
treated with rhEPO alone were not tested to minimize the
amount of experimental animals since electrophysiologi-
cal alterations were not observed.
Accumulation of Cisplatin-DNA adducts in DRG cells
The formation of drug-induced DNA adducts is assumed
to initially trigger apoptotic processes in DRG cells finally
resulting in sensory neuropathy [23,24]. Employing a
recently established monoclonal antibody-based immu-
noassay coupled with quantitative image analysis enabled
us to measure structurally defined DNA platination prod-
ucts in individual cell nuclei [25]. The method was previ-
ously shown to provide dose-dependent results in
cisplatin-exposed cells as well as in various tissue sections
from treated mice. The accumulation of unrepaired Pt-GG
lesions in DRG neurons during repetitive exposure to cis-
platin coincided with the onset of PNP in mice [11]. Here
we investigated the role of rhEPO in modulating the rates
of formation or repair of DNA lesions and measured the
adduct concentration in the nuclei of DRG cells (Figure
3). After a cumulative dose of 16 mg cisplatin/kg the mean
values of Pt-GG levels in DRG neurons did not exhibit sig-
nificant differences (1,7 ± 0,1 vs. 1,7 ± 0,2; mean ± SD)
between mice treated with cisplatin alone or in combina-
tion with rhEPO (Figure 3C).
Histopathological alterations
To examine whether the functional impairment of the
sensory nerve system after repetitive treatment with cispl-
atin is associated with morphological alterations or sub-
cellular damage in the pertaining tissues, we analyzed sec-
tions of the sciatic nerve by electron microscopy. Various
degenerative alterations were found in tissue sections
from mice of the cisplatin group with abnormalities in
myelinated fibers to be most prominent (Figure 4A). The
layers of myelin sheaths were split up. Additionally, the
diameter of mitochondria was increased in those axons
and edema or lysis of christae was obvious (Figure 4C). In
both groups treated with rhEPO the splitting of myelin
sheaths was not observed (Figure 4B). Remarkably, in
both groups treated with rhEPO a significant increase of
intact mitochondria was observed in the axoplasm com-
pared to cisplatin- and control-group (Figure 4E). In sum-
Impact of recombinant erythropoietin on cisplatin-induced neurophysiological impairment Figure 1 (see previous page)
Impact of recombinant erythropoietin on cisplatin-induced neurophysiological impairment. C57Bl/6 mice were 
repeatedly injected with cisplatin (2 mg/kg, i.p; 1×/week) or with cisplatin plus rhEPO (40 μg/kg, s.c.; 3×/week) or with rhEPO 
alone (40 μg/kg, sc; 3×/week) for 8 weeks. The control group was injected with saline alone (500 μl i.p.; 1×/week). Electrophys-
iological examinations of sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) and the 
corresponding M- and H-amplitude were performed in week 9. Columns represent group (n = 10) mean values ± SEM. Differ-
ences were highly significant (p < 0.001; multiple t-test with Bonferroni corrections) for SNCV values of cisplatin vs. control, 
for cisplatin vs. cisplatin + rhEPO groups and for cisplatin vs. rhEPO and were marginally affected for MNCV values of cisplatin 
vs. control groups (p > 0.05). Differences between the corresponding M- or H-amplitudes of cisplatin vs. control, for cisplatin 
vs. cisplatin + rhEPO and cisplatin vs. rhEPO groups were significant as well (p < 0.05). All other differences for SNCV or 
MNCV values were not significant (p > 0.05). I: p < 0.001; II: p < 0.05.
Recombinant erythropoietin partly preserved the tactile sen- sitivity Figure 2
Recombinant erythropoietin partly preserved the 
tactile sensitivity. Mice were treated as in Figure 1 and 
were examined in week 9 for the mechanical sensitivity using 
the von Frey hair method and recording of the 50% with-
drawal threshold. Columns represent group mean ± SEM 
from repeated measurements of 10 animals per group. 
Mechanical withdrawal thresholds were significantly reduced 
in the cisplatin group (p < 0.001, multiple t-test with Bonfer-
roni corrections). The difference between cisplatin + rhEPO 
vs. control group was also significant (p = 0.026), while the 
comparison of cisplatin vs. cisplatin + rhEPO group indicated 
a restoration of the tactile sensitivity but lacked statistical sig-
nificance (p = 0.313).BMC Neuroscience 2009, 10:77 http://www.biomedcentral.com/1471-2202/10/77
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mary, i) morphologically damaged mitochondria were
observed solely in neuronal cells of the cisplatin group
and were absent in rhEPO treated group and ii) in both
groups treated with rhEPO a significant increase of intact
mitochondria was observed.
Discussion and conclusion
In the current study we found that rhEPO ameliorated cis-
platin-induced neuropathy in mice. As previously shown,
we found no effect on electrophysiological parameters by
rhEPO alone [26]. The compound improved electrophys-
iological and morphological parameters, but did not
interfere with the accumulation of Pt-DNA adducts in crit-
ical neuronal cells. Our findings suggest that the neuro-
protective effects are mediated by improving the cell
resistance to side effects of Cisplatin rather than by influ-
encing the formation or repair rates of cisplatin-induced
cross-links in the nuclear DNA of DRG cells.
The primary target structures in the nervous system are the
DRG cells and loss of function or cell apoptosis in DRG
cells are hallmarks of sensory neuropathy [24]. Spectro-
scopic post mortem analysis of various neuronal tissues
from patients treated with cisplatin revealed high concen-
trations of platinum in the DRG [3]. More recent studies
confirmed this by demonstrating augmented levels of pla-
tination products in the nuclear DNA of DRG neurons
and satellite cells of cisplatin-exposed mice [27]. By ana-
lyzing two syngenic mouse strains [11] either proficient or
deficient for nucleotide excision repair (NER), we showed
that the severity of cisplatin-induced neuropathy was sig-
nificantly correlated with the amount of persisting Pt-
DNA adducts in DRG cells. Our findings suggest a possi-
ble relationship between the extent of DNA platination
and the degree of sensory impairment.
As the NER mechanism does not only take care of the
integrity of the bulk nuclear DNA but is even more effi-
cient in removing damage from actively transcribed genes,
it is still unclear whether persisting cisplatin adducts in
that sub-fraction of the genome play a particular role in
triggering functional loss or demise of DRG cells. Due to
the excessive energy consumption of neuronal cells and
the observed structural damage in mitochondria, drug-
induced damage in the mitochondrial DNA (mtDNA) has
been suggested to cause the functional impairment. How-
ever, as the NER system efficiently protects mice from cis-
platin-induced neuropathy by not acting on the
mitochondrial genome [28], it is very unlikely that accu-
mulated platination products in mtDNA play a major role
in this process.
Until now, the direct molecular link by which persisting
intrastrand cross links in nuclear DNA trigger the loss of
mitochondrial integrity and the functional impairment in
cisplatin-exposed neuronal cells is unclear. Experiments
with explanted, cisplatin-exposed DRG neurons demon-
strated the translocation of cytosolic Bax protein to the
Immunostaining of DRG and measurement of Pt-GG adduct level Figure 3
Immunostaining of DRG and measurement of Pt-GG adduct level. Visualization and measurement of Pt-(GG) intras-
trand cross-links in the nuclear DNA of DRG neurons of C57 Bl/6 mice after chronic treatment with cisplatin (cumulative 
dose: 16 mg/kg). Cryosections of dorsal root ganglia were immunostained with monoclonal antibody R-C18 for Pt-(GG) 
adducts (B) and with DAPI for nuclear DNA (A). Arrows indicate nuclei of neurons. C: Measurement of Pt-(GG) adduct levels 
in DRG neurons of mice treated with Cisplatin alone or in combination with rhEPO by quantitative image analysis of nuclear 
signals (AFU: arbitrary fluorescence units normalised for the DNA content of individual cells); means of >200 nuclei +/- SD.BMC Neuroscience 2009, 10:77 http://www.biomedcentral.com/1471-2202/10/77
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mitochondrial membrane with consecutive release of
cytochrome c from this organelle and the activation of
caspase 9 [29]. In this model the initial sensor for DNA
platination products remains obscure as well as the puta-
tive mechanism by which EPO exerts its protective effects.
Another attractive model encompasses the mutual antag-
onistic regulation of apoptosis and autophagy in mam-
malian cells [30]. The balance between both mechanisms
is determined amongst others by the minor cytosolic frac-
tion of the High-mobility group 1 protein (HMGB1)
which is a structurally conserved nuclear protein acting as
an architectural chromatin binding factor. As HMGB1 has
been shown to strongly bind to cisplatin-adducted
nuclear DNA [31], it can be hypothesized that the level of
free HMGB1 in the cytoplasm is diminished by such a
"nuclear trapping" process and, thereby, autophagy is
repressed, mitochondrial integrity is lost and apoptotic
mechanisms are activated.
In our mouse model we have demonstrated that the sci-
atic nerve revealed severe structural damage of the myelin
sheaths and the mitochondria in cisplatin treated mice.
Likewise, in streptozotocin-induced rats retinal neuronal
cells show similar morphological changes in mitochon-
dria that are diminished by rhEPO [32]. Parallel to mito-
chondrial protection rhEPO saved the myelin sheaths
from structural damage (Figure 4). A similar axon protec-
tive effect of rhEPO had been suggested previously [21].
Schwann cells were shown to abundantly express EPO
receptors and ligand binding led to the phosphorylation
of the Janus kinase-2 (JAK2) [19], which is associated with
anti-apoptotic processes. In a spinal nerve crush model
rhEPO protected DRG neurons against neuronal apopto-
sis by enhanced JAK2 phosphorylation [13]. Proteins of
the bcl-2 family, extracellular signal-regulated kinases and
the phosphatidylinositol 3-kinase/Akt seemed to be
involved in EPO-activated anti-apoptotic pathways as
well [33,16]. Binding of erythropoietin to its receptor
leads to an activation of the phosphatidylinositol 3-
kinase/Akt pathway and NF-kB pathway via phosphoryla-
tion resulting in an up regulation of antiapoptotic pro-
teins including XIAP and C-IAP2, subsequently blocking
the activation of specific cell-death proteases leading to
apoptosis [34]. Erythropoietin mediates its neuroprotec-
tive properties via cross-talk between JAK2 and the nuclear
factor-kB (NF-kB) [35]. More recently, it was shown for
neurons in the central nervous system that erythropoietin
mediates regeneration via JAK2 and the phosphatidyli-
nositol 3-kinase/Akt pathway [36].
Axonoprotection, mitochondrial protection and increased frequency of mitochondria by rhEPO Figure 4
Axonoprotection, mitochondrial protection and increased frequency of mitochondria by rhEPO. Electron micro-
scope scanning of the sciatic nerve from mice treated with cisplatin (A, C) or with cisplatin + rhEPO (B, D) show axonal degen-
eration with impaired mitochondria only in A and C. Here mitochondria show an increased volume and loss of integrity 
(arrows in C; arrowheads in C and D indicate intact mitochondria). Co-treatment with rhEPO resulted in significantly higher 
numbers of intact mitochondria within the axon (E) as compared to the cisplatin and the control group. Columns represent the 
mean number of mitochondria/axon section in 150 axons. To avoid redundant figures, axons with increased numbers of intact 
mitochondria with respect to rhEPO injection alone are not shown and to minimize the amount of figures lower magnification 
were excluded. Magnification in A, B: 7000-fold, C, D: 12.000-fold. Scale bar = 2 μm. I: p < 0.001.BMC Neuroscience 2009, 10:77 http://www.biomedcentral.com/1471-2202/10/77
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In summary, our study clearly demonstrated the high neu-
roprotective efficacy of rhEPO in the peripheral nervous
system with respect to neurophysiological functions and
for the morphological integrity. Additionally the somatic
hypersensitivity showed tendency to improvement. The
effect of rhEPO is not mediated by attenuated DNA
adduct formation or accelerated repair. The mitochon-
drial protection and significantly increased frequency of
the mitochondria might contribute to the neuroprotective
property of rhEPO. Further clinical trials of erythropoietin
in patients with peripheral neuropathy seem to be war-
ranted in the future.
Methods
Animals
Male C57Bl/6/J (group A-D, nA-D = 40) mice from the
breeding stock of the Institute for Cell Biology were used
throughout all experiments. Mice were housed under spe-
cific pathogen free (SPF) conditions with 12 h/12 h dark-
light cycle, fed with 1314 fortified standard diet
(Altromin, Germany) and water ad libitum. Mice were
aged 20 weeks at the time of behavioral testing and neu-
rophysiological examination. All experiments were
approved by the state animal welfare board (G-033/05Z).
Study design
Mice were randomly divided into four groups (group A-D,
nA-D = 40). All mice were treated for eight weeks. Group A
was treated with cisplatin (Platinex®, Bristol, Munich, Ger-
many) 2 mg/kg i.p. once per week and group B was addi-
tionally treated with rhEPO (Neorecormon®, Roche,
Basel, Switzerland) 40 μg/kg s.c. three times per week
[37]. To prevent renal damage all mice were injected with
500 μl saline i.p. after cisplatin injection. Group C were
treated with rhEPO 40 μg/kg s.c. three times per week and
group D were treated with saline 500 μl i.p. once per week.
In week eight all mice were tested for their renal function
prior to behavioural testing and nerve conduction velocity
studies. Thereafter, the mice were sacrificed, blood was
taken from the heart to quantify serum creatinine and the
sciatic nerves were removed for histological analysis.
Electrophysiological examination of motor and sensory 
nerve function
All electrophysiological examinations were carried out
under general anesthesia with Thiobutabarbital sodium
salt hydrate (Inactin®, Sigma; i.p. 50 μg/kg b.w.). Sensory-
and motor nerve conduction velocities were calculated
using recordings of H- and M- responses following stimu-
lation of sciatic/tibial nerves as described previously [38].
The compound muscle action potentials (CMAPs) elicited
by orthodromic conduction (M-response) and by the
monosynaptic reflex arc (H-response), were recorded
from the fourth interosseous muscle of the hind paw with
a pair of micro needle recording electrodes. After amplifi-
cation (INH 4-channel differential amplifier, Science
Products, Hofheim, Germany) the evoked action poten-
tials were sampled and analyzed by means of a CED
micro1401 system with the "Signal for Windows Version
2.05" software (Cambridge Electronic Design, Cam-
bridge, UK)
Peak-to-peak amplitudes of M- and H-responses were
measured. The response latencies (ms) were defined as the
interval between the stimulus artifact and the beginning
of the M- or H-response. The distance between the two
stimulation points was measured over the skin with the
hip and knee in a flexed position. Motor (MNCV) and H-
reflex-related sensory nerve conduction velocity (SNCV)
were calculated as follows:
MNCV [m/s] = distance (sciatic notch-ankle)/latency (M-
response sciatic notch - M-response ankle);
SNCV [m/s] = distance (sciatic notch-ankle)/latency (H-
response sciatic notch - H-response ankle). All groups
were blinded to the examiner.
Mechanical sensitivity
To assess changes in mechanical nociceptive thresholds,
mice were placed on a plastic mesh floor covered by trans-
parent plexiglas cages. For testing, mice were allowed to
acclimatize for 30 minutes. Successively greater diameter
von Frey nylon monofilaments (Stoelting, USA) were
applied to the hind paw. The mechanical sensitivity was
assessed using the up and down method [39]. The 50%
probability withdrawal threshold (force of the von Frey
hair to which an animal reacts to 50% of the presenta-
tions) was recorded. To reduce the amount of experimen-
tal animals a fourth group treated with rhEPO was
abdicated since rhEPO did not have any effect on the
nerve conduction velocity studies. All groups were
blinded to the examiner.
Electron microscopic examination of sciatic nerves
Sciatic nerves were fixed in 2.5% glutaraldehyde in phos-
phate buffer immediately after removal. After washing in
phosphate buffer, tissue samples were osmicated for 1 h
with 1%OsO4  in phosphate buffer, dehydrated in a
graded series of alcohols, and embedded in Epon 812
(Shell Chemical of Houston, Texas, USA). Electron micro-
scopic examination was performed using a Zeiss EM 902.
For statistical analysis of the mitochondria a total of 150
axons in 12 nerves each (3 × group A, 3 × group B, 3 ×
group C, 3× group D) were examined. All sections were
blinded to the examiner.BMC Neuroscience 2009, 10:77 http://www.biomedcentral.com/1471-2202/10/77
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Quantification of Pt-DNA adducts by the Immuno-
Cytological Assay (ICA)
Immunofluorescence staining and quantification of spe-
cific platinum adducts in the nuclear DNA was performed
essentially as described previously with some modifica-
tions [25]. Briefly, 7 μm thick DRG tissue sections were
fixed in methanol (12 h; -20°C) and rehydrated in PBS
(10 min; 25°C). After denaturation by alkali treatment
(60% 70 mM NaOH/140 mM NaCl, 40% methanol; 5
min, 0°C) cytoplasmic and nuclear proteins were digested
by incubation with pepsin (Sigma, 300 μg/ml in 20 mM
HCl; 10 min, 37°C). After blocking (1% casein/PBS; 30
min; 25°C) slides were immunostained for DNA adducts
with an anti-(Pt-GG) monoclonal antibody (MAB R-C18;
0.2 μg/ml) and with Cy3-rabbit anti-(rat-Ig) (Dianova,
Hamburg, Grermany). The DNA was counterstained with
DAPI (1 μg/ml PBS).
The quantification of fluorescence signals was performed
by a microscope-coupled digital image analysis system
(Zeiss Axioplan and ACAS 6.0 Image Analysis System,
Ahrens Electronics; Bargterheide, Germany). Adduct lev-
els in the nuclear DNA of individual cells were calculated
by normalizing antibody-derived fluorescence signals to
the corresponding DNA content of the same cell and are
expressed as arbitrary fluorescence units (AFU). Cryosec-
tions from 5 mice per group were analyzed. Mean values
± SEM of > 400 cells were calculated.
Renal function test
To test renal function, mice were placed in metabolic
cages for 24 hours and urine was collected in a cooled
(4°C) container to minimize evaporation. Thereafter
blood was taken from the heart. Creatinine levels were
determined in urine and serum samples using the Jaffé
method (ADVIA 1650 Chemistry System, Bayer Health
Care, Fernwald, Germany). Creatinine Clearance as a
marker of glomerular filtration was calculated as urine cre-
atinine × urine volume/serum creatinine × 1440 min. All
four groups were blinded to the examiner.
Statistical analysis
One factorial ANOVA (between subject factor GROUP: A
vs. B vs. C vs. D) was performed to compare mean ampli-
tudes of H- and M responses and mean sensory and motor
conduction velocities in the groups A-D. Post-hoc com-
parisons were performed with multiple T-tests with Bon-
ferroni corrections. The level of significance was 0.05.
Abbreviations
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